219 related articles for article (PubMed ID: 15984108)
1. How to avoid future Vioxx-type scandals.
Prescrire Int; 2005 Jun; 14(77):115-7. PubMed ID: 15984108
[TBL] [Abstract][Full Text] [Related]
2. Learning the value of drugs--is rofecoxib a regulatory success story?
Eisenberg RS
N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
[No Abstract] [Full Text] [Related]
3. Rofecoxib, Merck, and the FDA.
Villalba L; Witter J
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
[No Abstract] [Full Text] [Related]
4. Under surveillance.
Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
[No Abstract] [Full Text] [Related]
5. Vioxx's history and the need for better procedures and better testing.
Gilhooley M
Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
[No Abstract] [Full Text] [Related]
6. The lessons of Vioxx.
Frazier KC
N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
[No Abstract] [Full Text] [Related]
7. Journal grows suspicious of Vioxx data.
Wadman M
Nature; 2005 Dec; 438(7070):899. PubMed ID: 16355178
[No Abstract] [Full Text] [Related]
8. Rofecoxib, Merck, and the FDA.
Kim PS; Reicin AS
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
[No Abstract] [Full Text] [Related]
9. How to avoid another 'Vioxx'.
Frantz S
Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
[No Abstract] [Full Text] [Related]
10. The Vioxx debacle revisited.
Manthous CA
Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
[No Abstract] [Full Text] [Related]
11. The Vioxx debacle revisited.
Mohapatra PR; Janmeja AK
Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
[No Abstract] [Full Text] [Related]
12. The withdrawal of rofecoxib.
Arellano FM
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
[No Abstract] [Full Text] [Related]
13. Cox-2 inhibitors: still no decisive action.
Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408
[TBL] [Abstract][Full Text] [Related]
14. What ails the FDA?
Okie S
N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
[No Abstract] [Full Text] [Related]
15. Evaluating drug effects in the post-Vioxx world: there must be a better way.
Avorn J
Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
[No Abstract] [Full Text] [Related]
16. Discontinuation of Vioxx.
Garattini S; Bertelé V
Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
[No Abstract] [Full Text] [Related]
17. The vexations of Vioxx.
Sibbald B
CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046
[No Abstract] [Full Text] [Related]
18. The Vioxx debacle revisited.
Daikh DI
Am J Med; 2005 Sep; 118(9):1057. PubMed ID: 16164908
[No Abstract] [Full Text] [Related]
19. The sad story of Vioxx, and what we should learn from it.
Karha J; Topol EJ
Cleve Clin J Med; 2004 Dec; 71(12):933-4, 936, 938-9. PubMed ID: 15641522
[No Abstract] [Full Text] [Related]
20. Vioxx, the implosion of Merck, and aftershocks at the FDA.
Horton R
Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041
[No Abstract] [Full Text] [Related]
[Next] [New Search]